Responses to growth hormone (GH) treatment vary widely. There is a broad range of sensitivity — and responsiveness — to GH, so a ‘one size fits all’ approach to GH treatment is no longer appropriate.
The challenge facing endocrinologists is to deliver a personal approach that improves growth outcomes, safety and cost of treatment for each child.
iGRO™ is a web-based medical device that helps to deliver individualised GH treatment as soon as treatment starts: applying validated growth prediction algorithms developed using the wealth of real-world clinical data in KIGS (the Pfizer International Growth Database).
This enables you to evaluate a child’s potential to respond to GH treatment before it is initiated.
The intrinsic potential of an individual to grow in response to GH, independent of GH dose1
iGRO™ also helps to monitor the effect of GH treatment by comparing a child’s predicted and actual growth responses to GH each year: supporting evidence-based individualisation of GH therapy and helping patients and their families understand their growth potential.
Having a realistic expectation of the short and long-term effects of GH therapy is one of the most important factors for ensuring adherence to treatment.
iGRO™ prediction algorithms can explain up to 70% of variability in growth responses:
- 30–70% for children with IGHD
- 30–68% for girls with Turner syndrome
- 30–52% for short children born SGA
1 -MB Ranke et al. Towards Optimal Treatment with Growth Hormone in Short Children and Adolescents: Evidence and Theses. Horm Res Paediatr 2013;79:51–67
2 -Ranke et al. Observed and Predicted Growth Responses in Prepubertal Children with Growth Disorders: Guidance of Growth Hormone Treatment by Empirical Variables. J. Clin. Endocrinol. Metab. 2010;95:1229-1237